Peer-reviewed veterinary case report
New drug OP449 shows promise against canine T-cell lymphoma cells
By Fujiwara, Nobuyuki et al.·Published in The Journal of veterinary medical science·2013·Joint Faculty of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
- Species:
- dog
Plain-English summary
A study found that a new treatment called OP449 could help dogs with T-cell lymphoma, a common type of cancer in dogs. In laboratory tests, OP449 increased the activity of a protein that fights tumors and effectively killed cancer cells that had high levels of a specific protein called SET. This treatment caused the cancer cells to die through a process called apoptosis. While this is still in the research phase, it shows promise for improving outcomes in dogs with lymphoma, especially those that don't respond well to traditional chemotherapy.
People also search for: dog lymphoma treatment · canine cancer new therapies · OP449 for dog cancer
Abstract
Lymphoma is one of the most common malignant tumors in canine. Chemotherapy results in a high rate of remission; however, relapse and clinical drug resistance are usually seen within a year. Protein phosphatase 2A (PP2A) acts as a tumor suppressor and plays a critical role in mammalian cell transformation. Increased protein levels of SET, endogenous PP2A inhibitor, have been reported to correlate with poor prognosis in human leukemia. Here, we test the potential therapeutic role for a SET antagonist in canine lymphoma. We observed SET protein levels increased in multiple canine lymphoma cell lines compared with primary peripheral blood cells. A novel SET antagonist OP449 increased PP2A activity and effectively killed SET high-expressing canine lymphoma cells, but not SET low-expressing cells. Caspase-3 activation and enhanced Annexin V positive staining were observed after OP449 treatment, suggesting apoptotic cell death by OP449. Consistent with this, pan-caspase inhibitor Z-VAD-FMK blocked OP449 induced cell death. These data demonstrated the potential therapeutic application of SET antagonists for canine lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23131782/